Clinical Data New Taiho, Cullian data heats up lung cancer drug battle BioPharma DiveThe findings position their drug, zipalertinib, as a threat to multiple approved medicines while setting a bar for others in testing.OncologyRead full story pharminent August 13, 2026 (Last updated: August 14, 2026) BioPharma Dive The findings position their drug, zipalertinib, as a threat to multiple approved medicines while setting a bar for others in testing. Oncology Read full story Post navigation Previous: PTC takes a chance on Sangamo’s Fabry disease gene therapyNext: PTC Therapeutics Acquires Sangamo’s Fabry Disease Gene Therapy Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026